It Is Today: Texas Hemp Ban Takes Effect. Where Will THC Demand—and Revenue—Go Next?

Texas’ long-running battle over intoxicating hemp reached a decisive turning point Friday, as delta-8 THC and several other hemp-derived intoxicants became Schedule I controlled substances across the state.

The change taking effect July 31 does not eliminate every intoxicating hemp product sold in Texas. Hemp-derived delta-9 THC products containing no more than 0.3% delta-9 THC by dry weight can remain legal, including qualifying gummies, beverages and tinctures. But products containing manufactured delta-8, delta-10, THCP and other covered THC isomers now face criminal prohibition, while THCA flower is also expected to be swept into the crackdown.

That distinction will matter enormously to consumers, retailers and law enforcement. Texas has not created a clean, comprehensive ban on intoxicating hemp. It has instead redrawn the line between legal and illegal THC products through the state’s controlled-substance schedule, leaving a narrower delta-9 market operating beside an expanding—but still highly restrictive—medical cannabis program.

How Texas Accidentally Built a Multibillion-Dollar THC Market

The present conflict began with the 2018 Farm Bill, which removed hemp from the federal definition of marijuana. Congress defined hemp as cannabis containing no more than 0.3% delta-9 THC by dry weight, creating a legal distinction based primarily on the concentration of a single cannabinoid rather than on the product’s actual effects, whether those effects are viewed as therapeutic, psychoactive, or intoxicating.

Texas followed in 2019 with House Bill 1325, legalizing the production, manufacture, and sale of hemp and consumable hemp products that met the federal delta-9 threshold. What initially looked like an agricultural and CBD policy soon produced a much larger consumer market. Manufacturers learned to convert hemp-derived CBD into delta-8 and other psychoactive cannabinoids, while product developers used the dry-weight standard to sell gummies and beverages containing intoxicating doses of legal delta-9 THC.

In effect, Texas developed a broad commercial THC market without legalizing adult-use marijuana.

Hemp-derived products became available through smoke shops, convenience stores, specialty retailers, online sellers and beverage businesses, often without the limited physician access, product restrictions and vertically integrated licensing requirements that govern the state’s medical cannabis program.

The size of that market is difficult to measure because Texas does not track intoxicating hemp sales through a dedicated regulatory system comparable to state-licensed marijuana markets.

The most widely cited figures come from Whitney Economics research commissioned by industry organizations. Its 2025 analysis estimated that Texas’ hemp-cannabinoid sector generated approximately $5.5 billion in annual revenue, supported more than 53,000 jobs, produced around $2.1 billion in wages and created an estimated $10.3 billion in total economic activity. The report placed annual state sales-tax revenue near $268 million and counted more than 8,500 businesses participating in the market.

Those numbers should be understood as industry-backed estimates rather than independently audited state sales data. Even with that qualification, they illustrate the scale of the regulatory problem Texas created for itself: a market that began as an exception for hemp cultivation grew into one of the country’s largest commercial systems for selling intoxicating cannabinoids.

What Became Illegal Today—and What Did Not

Beginning July 31, Texas is reinstating language from its 2021 Schedule of Controlled Substances that treats THC isomers other than qualifying delta-9 THC as controlled substances. The Department of State Health Services says the scheduling action restores definitions that had been blocked by litigation since 2021.

For businesses, that means the fact that a cannabinoid began with federally legal hemp no longer necessarily protects the finished product under Texas law.

Commercially concentrated delta-8 THC, much of which is produced by converting hemp-derived CBD through chemical processes, now falls within Schedule I. The same regulatory interpretation reaches delta-10, THCP, and comparable manufactured THC variants.

THCA flower presents a related but technically distinct problem. THCA itself is not intoxicating until heat converts it into delta-9 THC, but Texas’ broader movement toward total-THC testing makes high-THCA flower difficult to defend as compliant hemp.

Current reporting indicates that THCA flower is among the categories businesses are being advised to remove, although separate litigation over Texas’ smokable-hemp rules has complicated enforcement.

Products containing compliant amounts of hemp-derived delta-9 THC remain legal. That includes some edibles, beverages and tinctures formulated to remain below the 0.3% dry-weight threshold. A gummy can therefore contain an intoxicating number of milligrams while still qualifying as hemp because the THC represents less than 0.3% of the product’s total weight.

CBD, CBG, and other non-intoxicating hemp products also do not become illegal merely because the delta-8 scheduling action takes effect. The practical result is not the disappearance of the Texas hemp industry, but a major contraction and product-level restructuring.

What This Means for Consumers and Businesses

For consumers, the stakes are no longer limited to whether a particular item can remain on a store shelf. Once a substance is treated as Schedule I, possessing it can trigger Texas criminal law.

Cannabis policy advocates told The Texas Tribune that possession of prohibited THC variants could be prosecuted as a state jail felony, carrying 180 days to two years in jail and fines of up to $10,000. The precise exposure in an individual case will depend on the substance, product weight, laboratory analysis, prosecutorial decisions, and the way Texas applies its penalty-group statutes.

That creates a difficult transition for people who purchased products legally before July 31 and may not understand that the same package can now carry criminal consequences.

Consumers are also unlikely to distinguish easily between delta-8, delta-9, delta-10, THCP and THCA based on branding alone, particularly where labels are incomplete or certificates of analysis are unavailable.

Joao Mitchell, legislative director of Texas Cannabis Collective and a manager at ATX Organics, estimated that his store would need to remove approximately half of its inventory. He said businesses less focused on naturally occurring delta-9 products could lose between 75% and 90% of their existing assortment.

The Constitutional and Administrative-Law Fight Behind the Ban

The most important legal detail is that the Texas Legislature did not pass a new delta-8 prohibition scheduled to take effect July 31.

The restriction comes from DSHS’ authority to update the Texas Schedule of Controlled Substances.

In 2021, the agency clarified its Schedule I definition of tetrahydrocannabinols to exempt only hemp containing no more than 0.3% delta-9 THC. Under that interpretation, other forms of THC—including manufactured delta-8 at any commercially significant concentration—remained controlled substances.

Hemp retailers and consumers sued. They argued that the 2019 Texas hemp law had legalized hemp derivatives and that DSHS exceeded its authority by using a scheduling decision and website guidance to criminalize products the Legislature had permitted. A trial court entered an injunction preventing the state from enforcing the delta-8 classification while the case proceeded.

On May 1, 2026, the Texas Supreme Court removed that barrier.

The court concluded that Texas lawmakers had decontrolled hemp and the compounds naturally present within the plant, but had not necessarily legalized manufactured products containing delta-8 concentrations dramatically higher than those occurring naturally. The court rejected the argument that the Legislature’s reference to hemp derivatives created an unlimited exemption for cannabinoids manufactured from legal hemp through laboratory conversion.

The court also emphasized the limits of judicial power. Justice Evan Young’s opinion found that the lower court’s injunction had intruded upon policy decisions assigned to the executive branch. Unless the Legislature clearly withdrew the health commissioner’s scheduling discretion, the judiciary could not treat the commissioner’s listing decision as an unauthorized act merely because it produced substantial economic consequences.

In layman’s terms, the industry argued that an agency should not be able to turn a legal product into a serious crime without lawmakers voting on it directly. The state responded that the Legislature had already authorized health officials to maintain the controlled-substance schedule and had never clearly legalized laboratory-manufactured THC variants.

The Supreme Court largely accepted the state’s position.

The ruling did recognize a theoretical distinction for trace amounts of naturally occurring delta-8 found within lawful hemp. The state represented that it did not intend to prosecute those practically undetectable amounts. But that concession offers little protection for commercial delta-8 products, whose concentrations far exceed those that naturally occur in the plant.

Abbott Blocked a Legislative Ban. The Courts Delivered a Narrower One.

The July 31 restrictions follow a years-long political battle over hemp in Texas. Lt. Gov. Dan Patrick pushed to ban intoxicating hemp products through Senate Bill 3, arguing the industry had become an unregulated recreational cannabis market. Gov. Greg Abbott vetoed the measure, saying an outright ban could face constitutional challenges and instead calling for strict regulation, including age limits, testing, labeling and stronger enforcement.

Lawmakers never reached agreement on a replacement, leaving regulators and the courts to shape the market. DSHS adopted broader hemp rules in 2026, while separate litigation over smokable hemp created ongoing uncertainty. Independently, the Texas Supreme Court upheld DSHS’ authority to classify manufactured delta-8 THC as a Schedule I controlled substance, clearing the way for the July 31 restrictions.

The Final Days: Retailers Prepare as the Market Shrinks

Ahead of July 31, retailers rushed to identify which products could remain on shelves, a process complicated by cannabinoid blends, chemically converted compounds and THCA products.

Cynthia Cabrera, chief strategy officer at Austin-based Hometown Hero, said the new rules create significant uncertainty and confirmed that, while her company would not challenge the Texas Supreme Court ruling, other businesses were preparing litigation. Meanwhile, Sarah Todd of the Texas Cannabis Policy Center warned the changes could revive the illicit market and criminalize consumers who had legally purchased hemp products for years.

Opponents of hemp-derived THC, however, say the fight is not over. While the July 31 action targets manufactured cannabinoids, compliant hemp-derived delta-9 THC products remain legal, and prohibition advocates continue pushing for broader restrictions.

The industry also faces another looming challenge: a federal hemp law scheduled to take effect in November 2026 would further narrow the definition of lawful hemp, potentially placing additional products outside the legal market unless Congress revises the legislation.

The Economic Impact: Closures, Write-Downs and a Forced Product Pivot

The first financial effect will be inventory impairment. The second effect will be revenue compression.

Businesses that survive will need to rebuild assortments around compliant delta-9, CBD and other non-prohibited cannabinoids while investing more heavily in testing, labeling, legal review and supplier verification. That favors larger or better-capitalized operators capable of absorbing compliance costs. Smaller stores that relied on high-margin converted cannabinoids face a greater risk of closure.

The wider economic impact remains uncertain. Industry estimates place Texas’ hemp-cannabinoid market at $5.5 billion in annual revenue, but Friday’s rule does not prohibit the entire amount. Some sales will remain within legal hemp. Some consumers will migrate to Texas’ medical program. Some will purchase marijuana from the illicit market, while others may stop buying altogether.

Industry participants estimate the new rules could remove 60% to 90% of the THC inventory carried by some retailers, increasing the risk of layoffs, store closures and consolidation. While demand for THC is unlikely to disappear, consumer spending is expected to shift toward compliant hemp-derived delta-9 products, Texas’ medical cannabis program and the illicit market.

Who Controls Texas’ Legal Medical Cannabis Market?

Texas’ crackdown arrives as the state is undertaking the largest expansion of its Compassionate Use Program since it began.

The program launched in 2015 and historically operated through only three vertically integrated dispensing organizations. House Bill 46 authorized DPS to issue 12 additional licenses, bringing the eventual statewide total to 15. The expansion also broadened qualifying conditions and improved the ability of operators to maintain inventory at satellite locations.

The timing creates an obvious competitive question: whether Texas is gradually redirecting cannabinoid consumers away from thousands of hemp retailers and toward a small group of tightly regulated medical operators.

Texas’ Medical Cannabis Industry Could Be the Biggest Beneficiary

As hemp-derived THC products disappear from thousands of retail shelves, Texas’ licensed medical cannabis operators could be the primary legal alternative for consumers—provided they can overcome the program’s limited access, physician requirements and higher costs.

Established Operators

• Texas Original – The state’s largest homegrown medical cannabis operator, with vertically integrated cultivation, manufacturing and statewide distribution.
• Goodblend (owned by SNDL Inc., NASDAQ: SNDL) – One of Texas’ three original licensees. Following SNDL’s acquisition of Parallel’s assets in July 2026, Goodblend now operates under SNDL and is well positioned to benefit from increased patient demand.
• Fluent – One of the original dispensing organizations, with statewide operations and an established patient network that could benefit from reduced hemp competition.

Conditional Licensees (Pending Final Texas DPS Approval)

Texas is expanding its Compassionate Use Program from three to a statutory maximum of 15 dispensing organization licenses. Following corrections to the state’s scoring process, 12 companies have been conditionally selected across Phase I and Phase II, although all remain subject to final due diligence and regulatory approval before they may begin operations.

• Verano Texas (Verano Holdings Corp., Cboe Canada: VRNO | OTCQX: VRNOF) – Region 10 (Far West Texas)
• Trulieve TX (Trulieve Cannabis Corp., CSE: TRUL | OTCQX: TCNNF) – Region 1 (Texas Panhandle)
• GTI Texas / RISE (Green Thumb Industries Inc., CSE: GTII | OTCQX: GTBIF) – Region 9
• PharmaCann (private) – Region 6 (Houston)
• Texas Patient Access (private) – Region 3 (Dallas–Fort Worth)
• Lonestar Compassionate Care Group (private) – Region 3 (Dallas–Fort Worth)
• Lone Star Bioscience (private) – Region 8 (San Antonio)
• Bluebonnet Technologies (private) – Region 6 (Houston)
• TexaRx (private) – Region 11 (South Texas)
• Texas Medica Collective (private) – Region 4
• Cresco Labs Texas (Cresco Labs Inc., CSE: CL | OTCQX: CRLBF) – Region 5
• Dilatso (private) – Region 2 (West & North-Central Texas)

If hemp-derived THC products continue to disappear from the Texas market, these operators could become the primary beneficiaries of consumers migrating into the state’s tightly regulated medical cannabis system.

Phase II Adds More Public Operators

In April 2026, Texas DPS added three more companies to its medical cannabis expansion under HB 46:

• Green Thumb Industries (CSE: GTII | OTCQX: GTBIF) – Region 9
• Texas Medica Collective – Region 4
• Cresco Labs (CSE: CL | OTCQX: CRLBF) – Region 5

Like all conditional licensees, they remain subject to due diligence and final approval before beginning operations.

Companies on Deck

Texas DPS also created an eligibility list to replace any applicant that fails the licensing process. It includes Village Farms (NASDAQ: VFF | TSX: VFF), Bluebonnet Technologies, Sawtooth Texas, Bayou City Medical Dispensary, Texas Apothecary, and several other applicants.

Texas Isn’t Eliminating THC Demand

Texas isn’t eliminating demand for THC—it’s redirecting it. As hemp-derived products disappear, consumers are likely to shift toward compliant delta-9 products, the state’s expanding medical cannabis program, or the illicit market.

For Texas Original, Goodblend, Fluent, and the new licensees, the hemp crackdown could become the industry’s biggest patient acquisition opportunity since the Compassionate Use Program was created.